New Guidance on Investigational Medicinal Products (IMPs) and Non Investigational Medicinal products (NIMPs)
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The EU Commission has published a revision of the Guidance on Investigational Medicinal Products (IMPs) and Non investigational Medicinal Products (NIMPs), which had been published in 2007, completing the detailed guidance CT-1. The main change relates to point 3.3 and the additional annex 2 setting out documentation requirements for NIMPs in the application dossier.
In 3.3., it is pointed out that documentation requirements in the application dossier for IMPs also apply to NIMPs. However, depending on the knowledge of the NIMP, documentation can be reduced to a so called 'simplified dossier' described in detail in Annex 2 of the document. To determine the required data, a risk-based approach needs to be applied.
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
11.12.2025Insurance Review in Phase 1 Clinical Trials
11.12.2025EMA Publishes Comments on ICH E21
27.11.2025Final ICH M14 Guideline on the Use of RWD for Safety Assessment
25.11.2025Clinical Trials: BMG publishes Standard Contractual Clauses Ordinance
04.11.2025UK Clinical Trials Regulations: Six-Month Countdown
04.11.2025Clinical Trials - Update on the CTIS